Latest The Hydration Pharmaceuticals Company (ASX:HPC) News

Hydralyte USA reported its strongest monthly sales in May 2025, alongside continued improvement in EBITDA losses, signaling steady progress toward profitability.

Hydralyte USA reports its best EBITDA performance since IPO, driven by strong sales and cost reductions, setting the stage for growth with upcoming product launches.

Hydralyte North America reported a 16% rise in Q1 FY25 net sales and improved gross margins, supported by a strategic capital raise and upcoming product launches targeting brain and gut health.

HydraLyte USA has completed the divestiture of its non-US assets, wiping out debt and boosting cash reserves to US$3.2 million, while focusing its growth strategy on the US ecommerce market with a 28% quarterly revenue increase.